WO2005017123A3 - Mptens as modifiers of the pten pathway and methods of use - Google Patents

Mptens as modifiers of the pten pathway and methods of use Download PDF

Info

Publication number
WO2005017123A3
WO2005017123A3 PCT/US2004/026492 US2004026492W WO2005017123A3 WO 2005017123 A3 WO2005017123 A3 WO 2005017123A3 US 2004026492 W US2004026492 W US 2004026492W WO 2005017123 A3 WO2005017123 A3 WO 2005017123A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mptens
modifiers
pten
pten pathway
Prior art date
Application number
PCT/US2004/026492
Other languages
French (fr)
Other versions
WO2005017123A2 (en
Inventor
Michael R Costa
Garth Joseph Mcgrath
Lynn Margaret Bjerke
Kim Lickteig
Original Assignee
Exelixis Inc
Michael R Costa
Garth Joseph Mcgrath
Lynn Margaret Bjerke
Kim Lickteig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Michael R Costa, Garth Joseph Mcgrath, Lynn Margaret Bjerke, Kim Lickteig filed Critical Exelixis Inc
Publication of WO2005017123A2 publication Critical patent/WO2005017123A2/en
Publication of WO2005017123A3 publication Critical patent/WO2005017123A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Human MPTEN genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of MPTEN are provided.
PCT/US2004/026492 2003-08-14 2004-08-12 Mptens as modifiers of the pten pathway and methods of use WO2005017123A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49504903P 2003-08-14 2003-08-14
US60/495,049 2003-08-14
US52454903P 2003-11-24 2003-11-24
US60/524,549 2003-11-24

Publications (2)

Publication Number Publication Date
WO2005017123A2 WO2005017123A2 (en) 2005-02-24
WO2005017123A3 true WO2005017123A3 (en) 2006-06-01

Family

ID=34198023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/026492 WO2005017123A2 (en) 2003-08-14 2004-08-12 Mptens as modifiers of the pten pathway and methods of use

Country Status (1)

Country Link
WO (1) WO2005017123A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012020839A1 (en) * 2010-08-12 2012-02-16 塩野義製薬株式会社 Pharmaceutical composition for cancer therapy
KR101540319B1 (en) * 2013-10-01 2015-07-30 한국생명공학연구원 Pharmacological composition containing a cyb5R3 protein or a polynucleotide encoding cyb5R3 for the prevention and treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150954A1 (en) * 2000-05-30 2002-10-17 Durden Donald L. Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
WO2005002418A2 (en) * 2003-06-19 2005-01-13 Exelixis, Inc. Mptens as modifiers of the pten/igf pathway and methods of use
WO2005003297A2 (en) * 2003-05-14 2005-01-13 Exelixis, Inc. Mptens as modifiers of the pten/igf pathway and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150954A1 (en) * 2000-05-30 2002-10-17 Durden Donald L. Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
WO2005003297A2 (en) * 2003-05-14 2005-01-13 Exelixis, Inc. Mptens as modifiers of the pten/igf pathway and methods of use
WO2005002418A2 (en) * 2003-06-19 2005-01-13 Exelixis, Inc. Mptens as modifiers of the pten/igf pathway and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KISHIMOTO H ET AL: "Physiological functions of PTEN in mouse tissues.", CELL STRUCTURE AND FUNCTION., vol. 28, 28 February 2003 (2003-02-28), pages 11 - 21 *
TORRES J ETAL: "Phosphorylation-regulated cleavage for the tumor suppressor PTEN by Caspase-3.", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 278, 3 June 2003 (2003-06-03), pages 30652 - 30660 *
VIROLLET ET AL: "EGR-1 transcription factor directly activates PTEN during irradiation induced signalling.", NATURE CELL BIOL., vol. 3, December 2001 (2001-12-01), pages 1124 - 1128 *

Also Published As

Publication number Publication date
WO2005017123A2 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
WO2007002088A3 (en) Psat1s as modifiers of the pten/akt pathway and methods of use
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2005002418A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2005003297A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004013309A3 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
WO2005090992A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2006099182A3 (en) Mptenakts as modifiers of the pten/akt pathway and methods of use
WO2005017123A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2004005483A3 (en) ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2004048538A3 (en) Csnks as modifiers of the rac pathway and methods of use
WO2004015071A3 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2005001026A3 (en) Adks as modifiers of the pten pathway and methods of use
WO2004005486A3 (en) Mp21s as modifiers of the p21 pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2004061123A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003074725A3 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
WO2005051310A3 (en) Ctpss as modifiers of the pten pathway and methods of use
WO2003074677A3 (en) MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
WO2003074673A3 (en) Lgals as modifiers of the chk pathway and methods of use
WO2005052134A3 (en) Ttbks as modifiers of the beta catenin pathway and methods of use
WO2005052130A3 (en) Nrbps as modifiers of the rac pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase